We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. Show more
Ask ADVFN Intelligence (AI)
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -5.62 | -17.0148349985 | 33.03 | 33.47 | 25.74 | 1094318 | 27.60225102 | CS |
| 4 | -6.45 | -19.0490253987 | 33.86 | 40.26 | 25.74 | 632747 | 32.16743473 | CS |
| 12 | -0.99 | -3.48591549296 | 28.4 | 40.26 | 25.74 | 560319 | 30.52739182 | CS |
| 26 | -8.89 | -24.4903581267 | 36.3 | 40.26 | 22.19 | 553607 | 29.16961351 | CS |
| 52 | 16.6 | 153.561517114 | 10.81 | 47.97 | 10.42 | 466993 | 30.02284825 | CS |
| 156 | 16.6 | 153.561517114 | 10.81 | 47.97 | 10.42 | 466993 | 30.02284825 | CS |
| 260 | 16.6 | 153.561517114 | 10.81 | 47.97 | 10.42 | 466993 | 30.02284825 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
